Skip to main content

Table 1 Characteristics and outcomes of study population by severity of LV dysfunction

From: Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

 

Moderate-severe (n = 15)

Mild (n = 27)

Minimal (n = 72)

P value

Clinical characteristics

 Age

55.7 ± 12.4

59.0 ± 9.6

55.9 ± 10.6

0.39

 Post-menopausal

9 (60%)

22 (81%)

50 (69%)

0.40

 Hypertension

4 (27%)

10 (37%)

25 (35%)

0.79

 Diabetes

1 (7%)

2 (7%)

12 (17%)

0.42

 Hyperlipidemia

1 (7%)

3 (11%)

9 (13%)

1.00

 Cigarette smoking (current)

2 (13%)

8 (30%)

10 (14%)

0.19

 Congestive heart failure

0

0

1 (1%)

1.00

 Valve disease

0

0

1 (1%)

1.00

 Arrhythmia

0

0

2 (3%)

1.00

 Coronary artery disease

0

1 (4%)

1 (1%)

0.60

 Stroke

0

0

0

N/A

 HF symptoms with LVEF decline

8 (53%)

4(15%)

15 (21%)

0.01

Cancer characteristics

 

 Left-sided cancer

9 (60%)

14 (52%)

39 (54%)

0.10

 Lymph node involvement

7 (47%)

14 (52%)

37 (51%)

0.94

Treatment characteristics

 

 Mastectomy

11 (73%)

24 (89%)

61 (85%)

0.42

 Radiation

13 (87%)

21 (78%)

53 (74%)

0.55

  Radiation dose (Gy)

55 (42.5,90)

80 (40,98.4)

53.75 (0,87.25)

0.45

 Anthracycline

15 (100%)

25 (93%)

61 (85%)

0.23

  Cumulative dose (mg/m2)

240 (240,240)

240 (150,240)

240 (150,240)

0.04

 Trastuzumab cycles received

7 (4,11)

14 (10,17)

16 (10,17)

0.002

 Trastuzumab interruption

15 (100%)

27 (100%)

67 (93%)

0.10

 Trastuzumab re-started

6 (40%)

16 (59%)

43 (60%)

0.36

 Completed planned trastuzumab

1 (7%)

10 (37%)

35 (49%)

0.01

Other management

 Cardiology referral

14 (93%)

21 (78%)

40 (56%)

0.006

 Beta blocker

15 (100%)

14 (52%)

28 (39%)

< 0.0001

 ACE inhibitor

15 (100%)

18 (67%)

38 (53%)

0.002

 Loop diuretic

9 (60%)

7 (26%)

8 (11%)

0.0001

 Mineralocorticoid receptor antagonist

9 (60%)

1 (4%)

1 (1%)

< 0.0001

Outcomes

 Breast cancer recurrence

3 (20%)

5 (19%)

12 (17%)

0.88

 All cause mortality

1 (7%)

4 (15%)

6 (8%)

0.64

  1. Values shown are counts (percentages), mean ± SD, or median (Q1,Q3). Abbreviations: ACE Angiotensin converting enzyme, HF Heart failure, LVEF Left ventricular ejection fraction